Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Clinical trial NCT05266612 · RECRUITING
Trial details
- NCT number
- NCT05266612
- Sponsor
- Virogin Biotech Canada Ltd
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-09
- Primary completion
- 2024-12-31
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.